SCHEMBL2479832

SCHEMBL2479832

NC(=O)c1cnc(Cl)cc1NCc1cccc(C(F)(F)F)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KB1 P23443 8/20 0.61
AURKA O14965 7/20 0.61
AURKB Q96GD4 1/20 0.61
HDAC3 O15379 1/20 0.53
HDAC1 Q13547 1/20 0.53
HDAC2 Q92769 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
RXFP1 Q9HBX9 1/20 0.51
JAK3 P52333 2/20 0.51
STAT6 P42226 1/20 0.49
VNN1 O95497 2/20 0.48
MAPK8 P45983 1/20 0.48
JAK2 O60674 1/20 0.48
JAK1 P23458 1/20 0.48
TYK2 P29597 1/20 0.48
IRAK4 Q9NWZ3 1/20 0.48
LMNA P02545 1/20 0.47
HPGD P15428 1/20 0.47
MEN1 O00255 1/20 0.47
PLA2G1B P04054 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2499437 0.88 RPS6KB1 (0.51) RPS6KB1AURKAAURKBJAK3VNN1
SCHEMBL2482408 0.87 ASPH (0.56) RPS6KB1AURKAAURKBHDAC3HDAC1
SCHEMBL2476348 0.85 JAK3 (0.52) RPS6KB1AURKAAURKBJAK3VNN1
SCHEMBL2475770 0.85 CDC7 (0.58) RPS6KB1AURKAAURKBJAK3STAT6
SCHEMBL2482471 0.84 RPS6KB1 (0.60) RPS6KB1AURKAAURKBHDAC3HDAC1
SCHEMBL2479323 0.84 JAK2 (0.51) RPS6KB1AURKAAURKBJAK3VNN1
SCHEMBL12456033 0.83 RPS6KB1 (0.54) RPS6KB1AURKAAURKBJAK3VNN1
SCHEMBL12301445 0.83 RPS6KB1 (0.44) RPS6KB1AURKAAURKBJAK3VNN1
SCHEMBL2480282 0.83 JAK3 (0.67) RPS6KB1JAK3STAT6JAK2JAK1
SCHEMBL12330858 0.82 JAK3 (0.51) RPS6KB1AURKAAURKBJAK3VNN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
CN-102227409-A Pyridine-3-carboxyamide derivative KOWA CO 2011-10-26 CN disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE JAK3, JAK1, UACA RPS6KB1 3316/4885AURKA 971/4885AURKB 1572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.